Resmetirom Efficacy Holds With GLP-1 or SGLT2 Background; Weight Loss Amplifies It

This prespecified secondary analysis of MAESTRO-NASH tells hepatology pharmacists how resmetirom performs when layered onto stable type 2 diabetes therapy and how modest weight loss modifies histologic response.

resmetiromTHR-beta agonistGLP-1 receptor agonistSGLT2 inhibitorMASHMASLDNASHliver fibrosisweight losstype 2 diabetessecondary analysisMAESTRO-NASH Gastroenterology / Hepatology

Background Information

Resmetirom shows promise in MASH, especially with weight loss.

The study examines the effects of resmetirom for metabolic-dysfunction associated steatohepatitis (MASH) in patients using glucose-lowering therapies like GLP-1 receptor agonists, which are common in diabetes management. Resmetirom was effective in improving MASH endpoints regardless of SGLT2 inhibitor or GLP-1 receptor agonist use, with greater efficacy observed in patients with ≥5% weight loss. Findings are relevant for managing MASH with resmetirom alongside diabetes therapies, highlighting the enhanced benefits with significant weight loss. Resmetirom efficacy in MASH is boosted by weight loss, unaffected by concurrent SGLT2 inhibitor or GLP-1 receptor agonist use.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Noureddin M, Rinella M, Taub R, Labriola D, Camacho RC, Alkhouri N, Loomba R, Bansal MB

Citation: Noureddin M, Rinella M, Taub R, et al. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Alimentary pharmacology & therapeutics. 2025;62(11-12):1089-1099. doi:10.1111/apt.70382

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →